# AGIO — Agios Pharmaceuticals · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AGIO  
**Sources:** 27  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-agio-agios-pharmaceuticals-catalysts-narrative-risks-5895

---

## Important framing

This is a point-in-time research snapshot as of **2026-10-03**. Figures are drawn from the provided sources, which were published at different dates (July–October 2026 for the freshest data; 2024–2025 for older background). Nothing below is investment advice. Where sources conflict or use different definitions, I flag it.

## Company and valuation snapshot (as of Oct 2, 2026)

Agios Pharmaceuticals (Nasdaq: AGIO) is a Cambridge, MA–based, commercial-stage biopharmaceutical company focused on rare diseases, particularly hemolytic anemias. Its lead product is mitapivat, marketed as **Pyrukynd** (PK deficiency) and **Aqvesme** (thalassemia) in the U.S. [[2]](https://finance.yahoo.com/healthcare/articles/agios-growth-story-hinges-mitapivats-132200618.html), [[8]](https://marketinference.com/analysis/r/2026/07/30/AGIO/), [[23]](https://www.marketbeat.com/stocks/NASDAQ/AGIO/). (Background/company history: [[24]](https://en.wikipedia.org/wiki/Agios_Pharmaceuticals). Pipeline overview: [[25]](https://www.agios.com/pipeline/), [[27]](https://www.linkedin.com/company/agios).)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-agio-agios-pharmaceuticals-catalysts-narrative-risks-5895 (free to sign up)._
